Synthesis, antileishmanial, antimalarial evaluation and molecular docking study of some hydrazine-coupled pyrazole derivatives

Table 2 Antimalarial activity test for the synthesized compounds at a dose of 48.46 µmol/kg*

Test compounds	Structure	Dose (mg/kg)	% Parasitemia	% Suppression	Mean survival time (day)
9		22.33	34.7 ± 4.1	33.3	8.6 ± 1.8
10		26.67	33.0 ± 6.7	36.5	6.8 ± 0.7
11		19.19	30.0 ± 6.7	42.3	8.7 ± 0.7
12		25.68	67.9 ± 3.7	− 30.5	7.8 ± 1.2
13		23.55	24.0 ± 1.7	53.9	9.5 ± 1.9
14		19.89	15.5 ± 4.1	70.2	9.0 ± 2.0
15		38.18	5.0 ± 1.4	90.4	7.7 ± 1.4
NC**	–	1 mL/100 g	52.0 ± 2.8	0.0	7.0 ± 1.2
CQ	–	25	0	100	ND

^*The equimolar concentration of the synthesized compounds as compared to the reference drug, CQ. **Values are mean ± standard deviations, p < 0.05. NC, negative control; CQ, chloroquine phosphate; ND, no mouse death was recorded during the study period

ISSN: 2661-801X